Experimental treatment combination, immunotherapy, (pembrolizumab), and targeted chemotherapy, (trametinib) for lung cancer

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Logo Image
"Help us evaluate the effects of the combination of immunotherapy and targeted chemotherapy on non-small cell lung cancer"
Age: 18-100
Healthy Volunteers: No
Keywords: advanced lung cancer, metastatic lung cancer
Type: Drug Study, Phase Ib
This study will be looking at two cancer drugs – pembrolizumab (MK-3475) and trametinib. Pembrolizumab (MK-3475) is FDA approved for the treatment of metastatic melanoma and metastatic lung cancer. Trametinib (targeted chemotherapy) is FDA approved for unresectable (unable to be removed with surgery) or metastatic melanoma cancers. Pembrolizumab (MK-3475) and trametinib are considered experimental in combination for this indication.
Pembrolizumab (MK-3475) is a highly selective antibody (immunotherapy) that is designed to move in the blood stream and attach to the surface of some white blood cells (WBCs). After this happens, the combined MK-3475/WBCs may begin attacking your tumor.
Researchers hope that the combination of pembrolizumab and trametinib will be safely tolerated and increase the effect on your body’s ability to fight your cancer.
This study requires

Please contact for details

Who can participate

Please contact for details

Benefits and risks of participating
You may not benefit from taking part in this research. The information we get from this study may help us to learn more about this study treatment, and this may help future cancer patients

Please contact for details concerning risks
Study duration and period
Recruitment period
From Aug. 14, 2017
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Leigh Anne Morris

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview